Navigation Links
Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
Date:9/4/2008

- 100 mg cohort demonstrates potent antiviral activity and favorable safety

profile -

CAMBRIDGE, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that it has completed the proof-of-concept study evaluating IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Data from the study demonstrate that the 100 mg/day cohort achieved a mean plasma viral load reduction of 1.87 log10 after seven days of treatment, similar to the potency observed with the other evaluated doses of 800 mg, 400 mg and 200 mg/day in this study. As with the other cohorts, no treatment-related serious adverse events were reported for any of the patients receiving 100 mg/day of IDX899 and no patients discontinued the study.

"We are pleased that HIV-1-infected patients receiving IDX899 in this trial achieved potent viral suppression at all doses tested," said Douglas Mayers, M.D., Idenix's chief medical officer. "With the promising antiviral activity and safety profile seen to date, especially at low doses, we believe that IDX899 could become an important part of combination antiretroviral therapy."

The phase I/II clinical trial was designed to evaluate the safety, tolerability, antiviral activity and pharmacokinetics of IDX899. Four cohorts of 800 mg/day, 400 mg/day, 200 mg/day and 100 mg/day were completed with ten HIV-1-infected treatment-naive patients randomized 8:2 in each cohort to receive oral once-daily IDX899 or matching placebo, respectively, for seven days.

P
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Net Medical Xpress ... telemedicine market, announced today the company has signed a ... staffing company based in Huntsville, AL ... specializes in the staffing and recruitment of telemedicine physicians. ... of the final agreement, which is expected by June ...
(Date:5/23/2013)... May 23, 2013  CAS Medical Systems, Inc. (NASDAQ: ... non-invasive patient monitoring, today announced that Thomas M. ... at the 2 nd Annual Marcum MicroCap Conference on ... New York City . The ... the Estate 10 room and will be available via a ...
(Date:5/23/2013)... NEW YORK , May 23, 2013  Intercept ... clinical stage biopharmaceutical company focused on the development and ... liver diseases, such as primary biliary cirrhosis, today announced ... and Chief Executive Officer, will present at the Deutsche ... Boston on Wednesday, May 29, 2013 ...
Breaking Medicine Technology:Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2
... Calif., Sept. 23 Preclinical data of a ... blood pressure) was presented Tuesday, September 21st, at ... Washington, DC, by Christopher D. Owens, MD, MSc, ... Endovascular Surgery, University of California, San Francisco. The ...
... that a new market research report is available ... Surgical Devices: Technologies and Global Markets ... THIS REPORT CONTAINS A focus on ... devices and total disc replacement (TDR) are becoming the ...
Cached Medicine Technology:Promising New Therapy for Drug-Resistant Hypertension Presented at Interventional Cardiology Meeting in Washington, D.C. 2Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 2Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 3Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 4Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 5Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 6Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 7Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 8Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 9Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 10Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 11Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 12Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 13Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets 14
(Date:5/23/2013)... its destruction inside a cell, a cancer-promoting growth ... the development of tumor-suppressing microRNAs (miRNAs) before it,s ... at Nature . , Under conditions of ... growth factor receptor (EGFR) gums up the cell,s ... at The University of Texas MD Anderson Cancer ...
(Date:5/23/2013)... drug about to be tested in a clinical trial ... treatment for Alzheimer,s disease has failed to work with ... patients, according to results of a study by University ... of neuroscience affiliated with the Evelyn F. and William ... emphasized the importance of verifying promising research results before ...
(Date:5/23/2013)... -- Mayo Clinic researchers have used next generation genomic ... prostate cancer tumors have similar genetic origins, which may ... today in the journal Cancer Research . , ... using next generation sequencing in adjacent Gleason patterns in ... changes in pathology," says ,John Cheville, M.D., Mayo Clinic ...
(Date:5/23/2013)... "triple negative" carries a poor prognosis, with limited treatment ... cancer cells the way it,s supposed to. New research ... respond to chemotherapy, and identifies a mechanism to rectify ... Li, PhD, and his team at Western,s Schulich School ... Numb functions to promote the death of cancer cells ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a ... the Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , ... those who are considering filing lawsuits. , The ... severe liver damage, according to a 2009 report from ... “safety communication,” the FDA warned consumers against using more ...
Breaking Medicine News(10 mins):Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
... could slow prostate cancer , , WEDNESDAY, April 29 (HealthDay ... citrus flavor, might help ward off painful calcium deposits ... which is known to inhibit calcium formation, according to ... presented Sunday at the American Urological Association annual meeting, ...
... over next 20 years, report warns , , WEDNESDAY, April 29 ... in the number of new cancers over the next two ... of minorities, a new report predicts. , Rates of ... among the population generally and by 67 percent among people ...
... /PRNewswire/ -- The Senate Finance Committee is ... that the Senate Finance Committee has shown a commitment ... health care system and is considering adopting many of ... We also appreciate that the Committee is considering several ...
... Speaker Nancy Pelosi spoke on the House floor this morning ... year 2010. The resolution passed the House by a vote of ... Senate later today. It does not require the signature of the ... it is indeed an honor to call Mr. Spratt a colleague. ...
... The Jonsson Cancer Center Foundation at UCLA ... Cure , May 1, 2009 at the Beverly Wilshire ... Dana Walden will receive the Gil Nickel Humanitarian Award, ... Barbara Fairchild, Editor-in-Chief, Bon Appetit Magazine; Jon Holman, President, ...
... 29 It is with great privilege that Avery ... Krieger, M.D., F.A.C.S. as Chief Clinical Liaison.Dr. Krieger,s expertise ... was Chief of Neurological Surgery at the University ... Based on that initial experience, Dr. Krieger went on ...
Cached Medicine News:Health News:Some Diet Sodas May Ward Off Kidney Stones 2Health News:Some Diet Sodas May Ward Off Kidney Stones 3Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 2Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 3Health News:Pelosi: Budget is a Blueprint for the Future 2Health News:Pelosi: Budget is a Blueprint for the Future 3Health News:Pelosi: Budget is a Blueprint for the Future 4Health News:UCLA's Jonsson Cancer Center Foundation 'Taste for a Cure' Honors Twentieth Century Fox Television Chairmen Dana Walden and Gary Newman 2Health News:Dr. Abbott J. Krieger Joins Avery Biomedical Devices, Inc. as Chief Clinical Liaison 2
...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Lumbar External Drainage System (LED) with Touhy needle is indicated for temporary access to the Lumbar Subarachnoid region as a means of draining cerebral spinal fluid (CSF) in order to reduce incre...
Monitorr ICP external CSF drainage system with self-contained ICP setting....
Medicine Products: